Compare FTHM & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FTHM | MURA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 36.0M |
| IPO Year | 2020 | N/A |
| Metric | FTHM | MURA |
|---|---|---|
| Price | $1.12 | $2.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $6.00 |
| AVG Volume (30 Days) | 115.2K | ★ 224.8K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $421,612,000.00 | N/A |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.78 | N/A |
| 52 Week Low | $0.65 | $0.95 |
| 52 Week High | $3.37 | $4.74 |
| Indicator | FTHM | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 40.39 |
| Support Level | $1.16 | $2.06 |
| Resistance Level | $1.27 | $2.10 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 8.73 | 25.00 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.